Catalona WJ - Search Results

1

Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation.

Gann PH, Ma J, Catalona WJ, Stampfer MJ. Gann PH, et al. Among authors: catalona wj. J Urol. 2002 Jun;167(6):2427-34. J Urol. 2002. PMID: 11992051

2

Prostate-specific antigen and screening for prostate cancer.

Han M, Gann PH, Catalona WJ. Han M, et al. Among authors: catalona wj. Med Clin North Am. 2004 Mar;88(2):245-65, ix. doi: 10.1016/S0025-7125(03)00188-3. Med Clin North Am. 2004. PMID: 15049577 Review.

3

Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml.

Kundu SD, Grubb RL, Roehl KA, Antenor JA, Han M, Catalona WJ. Kundu SD, et al. Among authors: catalona wj. J Urol. 2005 Apr;173(4):1116-20. doi: 10.1097/01.ju.0000155460.20581.a4. J Urol. 2005. PMID: 15758718

4

Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.

Eggener SE, Roehl KA, Catalona WJ. Eggener SE, et al. Among authors: catalona wj. J Urol. 2005 Aug;174(2):500-4. doi: 10.1097/01.ju.0000165203.40973.0f. J Urol. 2005. PMID: 16006880

5

More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects.

Jang TL, Han M, Roehl KA, Hawkins SA, Catalona WJ. Jang TL, et al. Among authors: catalona wj. Urology. 2006 Feb;67(2):343-8. doi: 10.1016/j.urology.2005.08.048. Epub 2006 Jan 25. Urology. 2006. PMID: 16442594

6

Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.

Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Loeb S, et al. Among authors: catalona wj. Urology. 2006 Feb;67(2):316-20. doi: 10.1016/j.urology.2005.08.040. Epub 2006 Jan 25. Urology. 2006. PMID: 16442597

7

Pathological characteristics of prostate cancer detected through prostate specific antigen based screening.

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JA, Yap RL, Catalona WJ. Loeb S, et al. Among authors: catalona wj. J Urol. 2006 Mar;175(3 Pt 1):902-6. doi: 10.1016/S0022-5347(05)00327-7. J Urol. 2006. PMID: 16469576

8

Prostate specific antigen density correlates with features of prostate cancer aggressiveness.

Kundu SD, Roehl KA, Yu X, Antenor JA, Suarez BK, Catalona WJ. Kundu SD, et al. Among authors: catalona wj. J Urol. 2007 Feb;177(2):505-9. doi: 10.1016/j.juro.2006.09.039. J Urol. 2007. PMID: 17222621

9

The association between total prostate specific antigen concentration and prostate specific antigen velocity.

Yu X, Loeb S, Roehl KA, Han M, Catalona WJ. Yu X, et al. Among authors: catalona wj. J Urol. 2007 Apr;177(4):1298-302; discussion 1301-2. doi: 10.1016/j.juro.2006.12.003. J Urol. 2007. PMID: 17382716

10

Under diagnosis and over diagnosis of prostate cancer.

Graif T, Loeb S, Roehl KA, Gashti SN, Griffin C, Yu X, Catalona WJ. Graif T, et al. Among authors: catalona wj. J Urol. 2007 Jul;178(1):88-92. doi: 10.1016/j.juro.2007.03.017. Epub 2007 May 11. J Urol. 2007. PMID: 17499308

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

523 results

Search Page

Filters